Article
A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial.
Arthritis research & therapy - 29 Sept 2017
Curtis Jeffrey R, Herrem Christopher, Ndlovu 'Matladi N, O'Brien Cathy, Yazici Yusuf
Abstract excerpt
BACKGROUND: Comorbidities may contribute to disease activity and treatment response in rheumatoid arthritis (RA) patients. We defined a somatization comorbidity phenotype (SCP) and examined its influence on response to certolizumab pegol (CZP) using data from the PREDICT trial. METHODS: Patients in PREDICT were randomized to the patient-reported Routine Assessment of Patient Index Data 3 (RAPID3) or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.